Novel RNA-targeting antisense therapy is shown to reduce lipoprotein(a) levels in 286 patients with existing atherosclerotic disease by upwards of 80% in a phase 2 clinical trial.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tsimikas, S. et al. J. Am. Coll. Cardiol. 71, 177–192 (2018).
Tsimikas, S. et al. N. Engl. J. Med. 382, 244–255 (2020).
Paré, G. et al. Circulation 139, 1472–1482 (2019).
Clarke, R. et al. N. Engl. J. Med. 361, 2518–2528 (2009).
Burgess, S. et al. JAMA Cardiol. 3, 619–627 (2018).
Thanassoulis, G. et al. N. Engl. J. Med. 368, 503–512 (2013).
de Oliveira Sá, M. P. B. et al. Curr. Atheroscler. Rep. 22, 2 (2020).
Boffa, M. B. & Koschinsky, M. L. Nat. Rev. Cardiol. 16, 305–318 (2019).
Willeit, P. et al. Lancet 392, 1311–1320 (2018).
Wilson, D. P. et al. J. Clin. Lipidol. 13, 374–392 (2019).
Varvel, S., McConnell, J. P. & Tsimikas, S. Arterioscler. Thromb. Vasc. Biol. 36, 2239–2245 (2016).
O’Donoghue, M. L. et al. Circulation 139, 1483–1492 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. J. R. serves on the Scientific Advisory Board for Alnylam, which makes small interfering RNA therapeutics, and for Novartis, which has licensed AKCEA-APO(a)-LRx.
Rights and permissions
About this article
Cite this article
Bajaj, A., Rader, D.J. Antisense oligonucleotides for atherosclerotic disease. Nat Med 26, 471–472 (2020). https://doi.org/10.1038/s41591-020-0835-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0835-2
